European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading

MT Newswires Live
18 Jul

European equities traded in the US as American depositary receipts were slightly higher late Friday morning, up 0.11% to 1,475.45 on the S&P Europe Select ADR Index, which ended the week more than 1% lower.

From continental Europe, the gainers were led by biopharmaceutical companies Genfit (GNFT) and DBV Technologies (DBVT), which advanced 2.6% and 5% respectively. They were followed by biopharmaceutical company Grifols (GRFS) and oil and gas company TotalEnergies (TTE), which were up 0.1% and 0.6% respectively.

The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and internet browser company Opera (OPRA), which fell 7% and 0.9% respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and internet advertising firm Criteo (CRTO), which were down 1.6% and 0.5% respectively.

From the UK and Ireland, the gainers were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Mereo BioPharma Group (MREO), which increased 2.5% and 3.1% respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and utilities company National Grid (NGG), which rose 1.5% and 0.7% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company NuCana (NCNA), which lost 4.9%. They were followed by biopharmaceutical company Akari Therapeutics (AKTX) and financial services company Barclays (BCS), which were off 0.1% and 0.8% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10